ANTI-PD-1 – ZIMBERELIMAB

Zimberelimab (zim) is a monoclonal antibody that binds PD-1, a well-established checkpoint of anti-cancer immunity.

Arcus is evaluating zimberelimab in combination with multiple molecules within the Arcus portfolio, including several registrational Phase 3 studies in non-small cell lung cancer and upper gastrointestinal cancers.

Zimberelimab is currently approved in China for the treatment of classical Hodgkin lymphoma and recurrent/metastatic cervical cancer. Gloria Biosciences secured the Chinese approval and holds commercial rights in China. It conducts its development activities independently of Arcus.